Lyudmila Bazhenova

Title(s)Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Research Interests
    Dr. Bazhenova’s clinical practice and research concentrate on lung cancer, particularly as this relates to females and non-smokers. She actively participates in cooperative group trials, and takes an active role in designing and implementing clinical investigations, including phase II studies and correlative science projects with several UCSD investigators. She believes in a multidisciplinary approach to lung cancer when radiation and surgery plays an important role in patient management. She leads a weekly lung tumor board, so patients can benefit from input of different sub-specialists

    Education and Training
    MD - Nizhny Novgorod State Medical Academy, Nizhny Novgorod, Russia - 1988-1994
    Resident, Chief Resident and Research Fellowship - Clinical Hospital #38,Nizhny Novgorod State Medical Academy Nizhny Novgorod, Russia - 1994-1995
    Intern/Resident - UCLA VA Medical Center - 1999-2002
    Fellowship - Hematology-Oncology, Scripps-Green Hospital, La Jolla, CA - 2002-2005

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Cancer Discov. 2022 Jul 06; 12(7):1676-1689. Wang M, Yang JC, Mitchell PL, Fang J, Camidge DR, Nian W, Chiu CH, Zhou J, Zhao Y, Su WC, Yang TY, Zhu VW, Millward M, Fan Y, Huang WT, Cheng Y, Jiang L, Brungs D, Bazhenova L, Lee CK, Gao B, Xu Y, Hsu WH, Zheng L, Jänne PA. PMID: 35404393; PMCID: PMC9262839.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. Invest New Drugs. 2022 Oct; 40(5):990-1000. Bauer T, Cho BC, Heist R, Bazhenova L, Werner T, Goel S, Kim DW, Adkins D, Carvajal RD, Alva A, Eaton K, Wang J, Liu Y, Yan X, Christensen J, Neuteboom S, Chao R, Pant S. PMID: 35767205; PMCID: PMC9395446.
      View in: PubMed   Mentions:    Fields:    
    3. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N Engl J Med. 2022 07 14; 387(2):120-131. Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, Der-Torossian H, Kheoh T, Velastegui K, Yan X, Christensen JG, Chao RC, Spira AI. PMID: 35658005.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    4. Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors. Clin Cancer Res. 2022 May 13; 28(10):2196. Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Lin JJ, Goto K, Lee J, Bazhenova L, John T, Fakih M, Chawla SP, Dziadziuszko R, Seto T, Heinzmann S, Pitcher B, Chen D, Wilson TR, Rolfo C. PMID: 35553647.
      View in: PubMed   Mentions:    Fields:    
    5. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clin Cancer Res. 2022 04 01; 28(7):1302-1312. Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Lin JJ, Goto K, Lee J, Bazhenova L, John T, Fakih M, Chawla SP, Dziadziuszko R, Seto T, Heinzmann S, Pitcher B, Chen D, Wilson TR, Rolfo C. PMID: 35144967.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    6. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Med. 2022 Jul; 11(14):2790-2800. Solomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Saintigny P, Wunder F, Raynaud J, Girard N, Lee JJ, Sulaiman R, Prouse B, Bresson C, Ventura H, Magidi S, Rubin E, Young B, Onn A, Leyland-Jones B, Schilsky RL, Lazar V, Felip E, Kurzrock R. PMID: 35307972; PMCID: PMC9302335.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    7. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. Lung Cancer. 2022 06; 168:74-82. Minchom A, Viteri S, Bazhenova L, Gadgeel SM, Ou SI, Trigo J, Bauml JM, Backenroth D, Bhattacharya A, Li T, Mahadevia P, Girard N. PMID: 35597172.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy. Transl Lung Cancer Res. 2022 Mar; 11(3):452-461. Yu L, Bazhenova L, Gold K, Tran L, Hilburn V, Vu P, Patel SP. PMID: 35399568; PMCID: PMC8988081.
      View in: PubMed   Mentions:
    9. Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC. Cancer Manag Res. 2022; 14:843-850. Yun KM, Bazhenova LA. PMID: 35250311; PMCID: PMC8890401.
      View in: PubMed   Mentions:
    10. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1). J Clin Oncol. 2022 Aug 10; 40(23):2530-2538. Ou SI, Jänne PA, Leal TA, Rybkin II, Sabari JK, Barve MA, Bazhenova L, Johnson ML, Velastegui KL, Cilliers C, Christensen JG, Yan X, Chao RC, Papadopoulos KP. PMID: 35167329; PMCID: PMC9362872.
      View in: PubMed   Mentions: 4     Fields:    
    11. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer. 2021 12; 162:154-161. Bazhenova L, Minchom A, Viteri S, Bauml JM, Ou SI, Gadgeel SM, Trigo JM, Backenroth D, Li T, Londhe A, Mahadevia P, Girard N. PMID: 34818606.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    12. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 01 20; 386(3):241-251. Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA, DESTINY-Lung01 Trial Investigators. PMID: 34534430; PMCID: PMC9066448.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    13. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Sep 01; 7(9):1368-1377. Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. PMID: 34264316; PMCID: PMC8283667.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    14. An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer. Expert Opin Pharmacother. 2021 Oct; 22(14):1815-1824. Schokrpur S, Hilburn V, Giustini N, Bazhenova L. PMID: 34225542.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2021 09; 159:56-65. Kozono DE, Stinchcombe TE, Salama JK, Bogart J, Petty WJ, Guarino MJ, Bazhenova L, Larner JM, Weiss J, DiPetrillo TA, Feigenberg SJ, Chen X, Sun Z, Nuthalapati S, Rosenwinkel L, Johnson EF, Bach BA, Luo Y, Vokes EE. PMID: 34311345.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    16. A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2021 08 15; 27(16):4566-4573. Garon EB, Spira AI, Johnson M, Bazhenova L, Leach J, Cummings AL, Candia A, Coffman RL, Janatpour MJ, Janssen R, Gamelin E, Chow LQM. PMID: 34108179.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    17. Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. Clin Cancer Res. 2021 08 01; 27(15):4160-4167. Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, Loong HH, McCoach CE, Weiss J, Kim YJ, Bazhenova L, Park K, Daga H, Besse B, Gautschi O, Rolfo C, Zhu EY, Kherani JF, Huang X, Kang S, Drilon A. PMID: 34088726; PMCID: PMC8447251.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    18. TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting. Target Oncol. 2021 05; 16(3):389-399. Bazhenova L, Lokker A, Snider J, Castellanos E, Fisher V, Fellous M, Nanda S, Zong J, Keating K, Jiao X. PMID: 33893941; PMCID: PMC8105201.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    19. Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs). Lung Cancer (Auckl). 2021; 12:21-34. Giustini N, Bazhenova L. PMID: 33790679; PMCID: PMC8006757.
      View in: PubMed   Mentions: 4  
    20. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov. 2021 07; 11(7):1688-1699. Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West HL, Mekhail T, Gentzler RD, Nguyen D, Vincent S, Zhang S, Lin J, Bunn V, Jin S, Li S, Jänne PA. PMID: 33632775; PMCID: PMC8295177.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    21. Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clin Res Rep. 2021 Feb; 2(2):100114. Yang JC, Reckamp KL, Kim YC, Novello S, Smit EF, Lee JS, Su WC, Akerley WL, Blakely CM, Groen HJM, Bazhenova L, Carcereny Costa E, Chiari R, Hsia TC, Golsorkhi T, Despain D, Shih D, Popat S, Wakelee H. PMID: 34589984; PMCID: PMC8474221.
      View in: PubMed   Mentions: 2  
    22. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020 12; 15(12):1907-1918. Yang JC, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, Chen J, Nikolinakos P, Lu Y, Pan H, Maniam A, Bazhenova L, Shirai K, Jahanzeb M, Willis M, Masood N, Chowhan N, Hsia TC, Jian H, Lu S. PMID: 32916310.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    23. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 08 27; 383(9):813-824. Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. PMID: 32846060; PMCID: PMC7506467.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansCTClinical Trials
    24. Commentary: Epidermal growth factor receptor mutations in resectable lung cancer: What is the prognostic importance? J Thorac Cardiovasc Surg. 2021 09; 162(3):676-677. Bazhenova L, Urbanic J, Onaitis M. PMID: 33581906.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Targeted Therapy. Clin Chest Med. 2020 06; 41(2):223-235. Giustini NP, Jeong AR, Buturla J, Bazhenova L. PMID: 32402358.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    26. ROS1-rearranged Non-small Cell Lung Cancer. Thorac Surg Clin. 2020 May; 30(2):147-156. Giustini NP, Bazhenova L. PMID: 32327173.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    27. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 02; 21(2):271-282. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators. PMID: 31838007; PMCID: PMC7461630.
      View in: PubMed   Mentions: 232     Fields:    Translation:Humans
    28. Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019 Oct 01; 5(10):1448-1455. Stinchcombe TE, Jänne PA, Wang X, Bertino EM, Weiss J, Bazhenova L, Gu L, Lau C, Paweletz C, Jaslowski A, Gerstner GJ, Baggstrom MQ, Graziano S, Bearden J, Vokes EE. PMID: 31393548; PMCID: PMC6692685.
      View in: PubMed   Mentions: 24     Fields:    
    29. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clin Cancer Res. 2020 01 15; 26(2):439-449. Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM. PMID: 31548343; PMCID: PMC6980768.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    30. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. J Transl Med. 2019 08 28; 17(1):294. Shishido SN, Carlsson A, Nieva J, Bethel K, Hicks JB, Bazhenova L, Kuhn P. PMID: 31462312; PMCID: PMC6714097.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    31. Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib. J Thorac Oncol. 2019 09; 14(9):1547-1555. Camidge DR, Pabani A, Miller RM, Rizvi NA, Bazhenova L. PMID: 31108247.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    32. On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. Clin Cancer Res. 2019 06 01; 25(11):3341-3351. Brown BP, Zhang YK, Westover D, Yan Y, Qiao H, Huang V, Du Z, Smith JA, Ross JS, Miller VA, Ali S, Bazhenova L, Schrock AB, Meiler J, Lovly CM. PMID: 30796031; PMCID: PMC6548651.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    33. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2019 03 15; 125(6):892-901. Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G. PMID: 30512189.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    34. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. Cancer Discov. 2019 03; 9(3):384-395. Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ. PMID: 30487236; PMCID: PMC6397691.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    35. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol. 2018; 2018. Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. PMID: 30637364; PMCID: PMC6329466.
      View in: PubMed   Mentions: 77     Fields:    
    36. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J Clin Oncol. 2018 09 10; 36(26):2693-2701. Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN. PMID: 29768119.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    37. Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment. Oncologist. 2018 10; 23(10):1236-1241. Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP. PMID: 29769383; PMCID: PMC6263128.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    38. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol. 2018 03 01; 29(3):687-693. Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Jänne PA, Yang JC. PMID: 29293889.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCTClinical Trials
    39. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys. 2018 05 01; 101(1):177-185. Urbanic JJ, Wang X, Bogart JA, Stinchcombe TE, Hodgson L, Schild SE, Bazhenova L, Hahn O, Salgia R, Vokes EE. PMID: 29487024; PMCID: PMC6173195.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    40. New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. Ther Adv Respir Dis. 2018 Jan-Dec; 12:1753466618794133. Villanueva N, Bazhenova L. PMID: 30215300; PMCID: PMC6144513.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    41. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018 01; 19(1):101-114. Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. PMID: 29169877; PMCID: PMC5847342.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    42. Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. Clin Cancer Res. 2018 01 01; 24(1):43-51. Subbiah V, Grilley-Olson JE, Combest AJ, Sharma N, Tran RH, Bobe I, Osada A, Takahashi K, Balkissoon J, Camp A, Masada A, Reitsma DJ, Bazhenova LA. PMID: 29030354.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    43. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clin Cancer Res. 2017 Oct 01; 23(19):5729-5736. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R. PMID: 28972084; PMCID: PMC5678984.
      View in: PubMed   Mentions: 90     Fields:    Translation:Humans
    44. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 11; 16(11):2598-2608. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 28835386; PMCID: PMC5670009.
      View in: PubMed   Mentions: 822     Fields:    Translation:HumansAnimalsCells
    45. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. Cancer Res. 2017 10 01; 77(19):5419-5427. Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R. PMID: 28807936; PMCID: PMC5626633.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    46. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clin Cancer Res. 2017 Sep 01; 23(17):5101-5111. Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R. PMID: 28539465; PMCID: PMC5581668.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    47. Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. Cancer Epidemiol Biomarkers Prev. 2017 07; 26(7):1139-1145. Boffa DJ, Graf RP, Salazar MC, Hoag J, Lu D, Krupa R, Louw J, Dugan L, Wang Y, Landers M, Suraneni M, Greene SB, Magaña M, Makani S, Bazhenova L, Dittamore RV, Nieva J. PMID: 28446544; PMCID: PMC5500408.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    48. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. PMID: 27836716.
      View in: PubMed   Mentions: 113     Fields:    Translation:HumansCTClinical Trials
    49. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1643-1652. Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, Han JY, Juan O, Dunphy F, Nishio M, Kang JH, Majem M, Mann H, Cantarini M, Ghiorghiu S, Mitsudomi T. PMID: 27751847.
      View in: PubMed   Mentions: 236     Fields:    Translation:HumansCTClinical Trials
    50. Ovarian stimulation in young adult cancer survivors on targeted cancer therapies. Fertil Steril. 2016 Nov; 106(6):1475-1478. Su HI, Connell MW, Bazhenova LA. PMID: 27565250; PMCID: PMC5159276.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    51. Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. Clin Lung Cancer. 2017 01; 18(1):34-42.e2. Leighl NB, Rizvi NA, de Lima LG, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, Singh M, Steinberg J, Juergens RA, Gadgeel SM. PMID: 27686971; PMCID: PMC5474312.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    52. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw. 2016 07; 14(7):825-36. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 27407123.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    53. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016 03; 14(3):255-64. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 26957612.
      View in: PubMed   Mentions: 169     Fields:    Translation:Humans
    54. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016 04; 15(4):743-52. Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. PMID: 26873727.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    55. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. PMID: 26418953; PMCID: PMC4741715.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    56. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015 Nov; 51(16):2321-9. Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD, Chu Q, Dunlop DJ, Jain M, Garon EB, Davis CS, Carrier E, Moses SC, Shawler DL, Fakhrai H. PMID: 26283035.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCTClinical Trials
    57. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer. 2015 Sep; 89(3):357-9. Klempner SJ, Bazhenova LA, Braiteh FS, Nikolinakos PG, Gowen K, Cervantes CM, Chmielecki J, Greenbowe JR, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH. PMID: 26187428.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    58. Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw. 2015 May; 13(5):515-24. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M, National comprehensive cancer network. PMID: 25964637.
      View in: PubMed   Mentions: 172     Fields:    Translation:Humans
    59. Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget. 2015 Mar 20; 6(8):6029-39. Tsigelny IF, Wheler JJ, Greenberg JP, Kouznetsova VL, Stewart DJ, Bazhenova L, Kurzrock R. PMID: 25760241; PMCID: PMC4467419.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    60. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. Cell Cycle. 2015; 14(8):1252-9. Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R. PMID: 25695927; PMCID: PMC4614867.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    61. Entropy, complexity, and Markov diagrams for random walk cancer models. Sci Rep. 2014 Dec 19; 4:7558. Newton PK, Mason J, Hurt B, Bethel K, Bazhenova L, Nieva J, Kuhn P. PMID: 25523357; PMCID: PMC4894412.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    62. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw. 2014 Dec; 12(12):1738-61. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 25505215.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    63. The thrombotic potential of circulating tumor microemboli: computational modeling of circulating tumor cell-induced coagulation. Am J Physiol Cell Physiol. 2015 Feb 01; 308(3):C229-36. Phillips KG, Lee AM, Tormoen GW, Rigg RA, Kolatkar A, Luttgen M, Bethel K, Bazhenova L, Kuhn P, Newton P, McCarty OJ. PMID: 25411332; PMCID: PMC4312838.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    64. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 01; 20(23):5927-36. Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. PMID: 25231400; PMCID: PMC4252585.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCTClinical Trials
    65. Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer. J Thorac Oncol. 2014 Aug; 9(8):1111-9. Carlsson A, Nair VS, Luttgen MS, Keu KV, Horng G, Vasanawala M, Kolatkar A, Jamali M, Iagaru AH, Kuschner W, Loo BW, Shrager JB, Bethel K, Hoh CK, Bazhenova L, Nieva J, Kuhn P, Gambhir SS. PMID: 25157764; PMCID: PMC4145608.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    66. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. J Neurooncol. 2014 Sep; 119(2):361-8. Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni DE, Kesari S. PMID: 24942463.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    67. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist. 2014 Jun; 19(6):631-6. Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R. PMID: 24797821; PMCID: PMC4041669.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    68. Adrenal metastases in lung cancer: clinical implications of a mathematical model. J Thorac Oncol. 2014 Apr; 9(4):442-6. Bazhenova L, Newton P, Mason J, Bethel K, Nieva J, Kuhn P. PMID: 24736064; PMCID: PMC3989547.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    69. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation. Ther Adv Respir Dis. 2014 Feb; 8(1):3-12. Haidar YM, Rahn DA, Nath S, Song W, Bazhenova L, Makani S, Fuster MM, Sandhu AP. PMID: 24334338.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    70. Stereotactic body radiation therapy in octogenarians with stage I lung cancer. Clin Lung Cancer. 2014 Mar; 15(2):131-5. Sandhu AP, Lau SK, Rahn D, Nath SK, Kim D, Song WY, Gulaya S, Fuster MM, Bazhenova L, Mundt AJ. PMID: 24157245.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    71. An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer. PLoS One. 2013; 8(7):e67733. Nair VS, Keu KV, Luttgen MS, Kolatkar A, Vasanawala M, Kuschner W, Bethel K, Iagaru AH, Hoh C, Shrager JB, Loo BW, Bazhenova L, Nieva J, Gambhir SS, Kuhn P. PMID: 23861795; PMCID: PMC3702496.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    72. Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer. J Thorac Dis. 2013 Apr; 5(2):E53-7. Randall JM, Bharne AA, Bazhenova LA. PMID: 23585959; PMCID: PMC3621950.
      View in: PubMed   Mentions: 1  
    73. Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model. Cancer Res. 2013 May 01; 73(9):2760-9. Newton PK, Mason J, Bethel K, Bazhenova L, Nieva J, Norton L, Kuhn P. PMID: 23447576; PMCID: PMC3644026.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    74. Clinic-based depression screening in lung cancer patients using the PHQ-2 and PHQ-9 depression questionnaires: a pilot study. Support Care Cancer. 2013 May; 21(5):1503-7. Randall JM, Voth R, Burnett E, Bazhenova L, Bardwell WA. PMID: 23325092.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    75. [The proteins of fast phase of inflammation in prognosis of condition of newborn in case of pregnancy complicated by hydramnion and under the risk of intrauterine infection]. Klin Lab Diagn. 2012 Jun; (6):22-5. Botvin'eva IA, Renge LV, Zorina RM, Bazhenova LG, zorina VN. PMID: 22946221.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    76. A stochastic Markov chain model to describe lung cancer growth and metastasis. PLoS One. 2012; 7(4):e34637. Newton PK, Mason J, Bethel K, Bazhenova LA, Nieva J, Kuhn P. PMID: 22558094; PMCID: PMC3338733.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    77. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol. 2012 Feb; 9(1):016001. Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P. PMID: 22306705; PMCID: PMC3387999.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCells
    78. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. Phys Biol. 2012 Feb; 9(1):016005. Wendel M, Bazhenova L, Boshuizen R, Kolatkar A, Honnatti M, Cho EH, Marrinucci D, Sandhu A, Perricone A, Thistlethwaite P, Bethel K, Nieva J, Heuvel Mv, Kuhn P. PMID: 22307026; PMCID: PMC3387995.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCellsCTClinical Trials
    79. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol. 2012 Feb; 9(1):016003. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P. PMID: 22306768; PMCID: PMC3387996.
      View in: PubMed   Mentions: 138     Fields:    Translation:HumansCells
    80. High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. Phys Biol. 2012 Feb; 9(1):016004. Nieva J, Wendel M, Luttgen MS, Marrinucci D, Bazhenova L, Kolatkar A, Santala R, Whittenberger B, Burke J, Torrey M, Bethel K, Kuhn P. PMID: 22306961; PMCID: PMC3388002.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCellsCTClinical Trials
    81. Hypofractionated radiotherapy as definitive treatment of stage I non-small cell lung cancer in older patients. Am J Clin Oncol. 2011 Jun; 34(3):254-8. Ahmad E, Sandhu AP, Fuster MM, Messer K, Pu M, Nobiensky P, Bazhenova L, Seagren S. PMID: 20562588.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    82. Frameless image-guided stereotactic body radiation therapy for lung tumors with 4-dimensional computed tomography or 4-dimensional positron emission tomography/ computed tomography. Clin Lung Cancer. 2011 May; 12(3):180-6. Nath SK, Sandhu AP, Jensen L, Kim D, Bharne A, Nobiensky PD, Lawson JD, Fuster MM, Bazhenova L, Song WY, Mundt AJ. PMID: 21663861.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    83. Locoregional and distant failure following image-guided stereotactic body radiation for early-stage primary lung cancer. Radiother Oncol. 2011 Apr; 99(1):12-7. Nath SK, Sandhu AP, Kim D, Bharne A, Nobiensky PD, Lawson JD, Fuster M, Bazhenova L, Song WY, Mundt AJ. PMID: 21429608.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    84. A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature. J Cancer. 2011 Mar 10; 2:153-64. Demoor PA, Matusov Y, Kelly C, Kolan S, Barnachea L, Bazhenova LA. PMID: 21475720; PMCID: PMC3053538.
      View in: PubMed   Mentions: 3  
    85. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):2044-6. Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ. PMID: 21102269.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    86. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010 Apr 15; 16(8):2450-7. Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. PMID: 20332327.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCTClinical Trials
    87. Definitive radiation therapy for stage I non-small-cell lung carcinoma: institutional experience with contemporary conformal planning. Clin Lung Cancer. 2009 Nov; 10(6):433-7. Sandhu AP, Messer K, Fuster MM, Ahmad E, Pu M, Bazhenova L, Rose M, Seagren S. PMID: 19900862.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    88. [Various acute phase reactants in different types of proliferative diseases of the uterine appendages]. Klin Lab Diagn. 2009 Oct; (10):16-9. Zorina VN, Kozlov IG, Tret'iakova TV, Promzeleva NV, Bazhenova LG, Zorina RM, Riabicheva TG, Zorin NA. PMID: 20000108.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    89. Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins. Proc Natl Acad Sci U S A. 2009 Jul 07; 106(27):11125-30. Page LJ, Suk JY, Bazhenova L, Fleming SM, Wood M, Jiang Y, Guo LT, Mizisin AP, Kisilevsky R, Shelton GD, Balch WE, Kelly JW. PMID: 19549824; PMCID: PMC2708763.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    90. [The serum levels of inflammatory reactants in women with inflammatory diseases of the uterine appendages, who participate in the in-vitro fertilization]. Klin Lab Diagn. 2008 Feb; (2):15-7. Markina LA, Zorina VN, Shramko SV, Zorina RM, Arkhipova SV, Bazhenova LG. PMID: 18354915.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    91. Terminal respiratory unit type lung adenocarcinoma is associated with distinctive EGFR immunoreactivity and EGFR mutations. Appl Immunohistochem Mol Morphol. 2007 Sep; 15(3):242-7. Peterson MR, Piao Z, Bazhenova LA, Weidner N, Yi ES. PMID: 17721266.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    92. [The level of pregnancy-associated alpha2-glycoprotein and the hormonal background during different options of hormonal replacement therapy in the menopausal syndrome]. Klin Lab Diagn. 2007 Jul; (7):24-7. Zorina VN, Predeina EM, Zorina RM, Levchenko VG, Bazhenova LG, Zorin NA. PMID: 17802803.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    93. Intravascular lymphoma: a role for single-agent rituximab. Leuk Lymphoma. 2006 Feb; 47(2):337-41. Bazhenova L, Higginbottom P, Mason J. PMID: 16321868.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    94. Reactive thrombocytosis associated with a pheochromocytoma. Thromb Haemost. 2005 Aug; 94(2):460-2. Bazhenova L, Du EZ, Bhoyrul S, McCallum J, Saven A. PMID: 16113840.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    95. SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. Br J Haematol. 2005 Jun; 129(6):791-4. Mena-Duran AV, Togo SH, Bazhenova L, Cervera J, Bethel K, Senent ML, Nieva J, Sanz GF, Sanz MA, Saven A, Mustelin T. PMID: 15953006.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans